Adoption of array technologies into the clinical laboratory

Expert Review of Molecular Diagnostics

Volumn 5, Issue 3, 2005, Pages 409-420

  Hadd, Andrew G ^a   Brown, Justin T ^a   Andruss, Bernard F ^a   Ye, Fei ^a   WalkerPeach, Cindy R ^a  

^a APPLIED BIOSYSTEMS   (United States)

Author keywords

Ashkenazi carrier screening; Cystic fibrosis; Diagnostics; Genetic testing; Leukemia; Luminex; Microarrays; MicroRNA; Multiplex; Oncology; PCR

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA;

BIOTECHNOLOGY; CLINICAL LABORATORY; COMPARATIVE GENOMIC HYBRIDIZATION; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DNA MICROARRAY; FLUORESCENCE MICROSCOPY; GENE FUNCTION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; IMMOBILIZED BEAD ARRAY; LEUKEMIA; LIQUID BEAD ARRAY; METHODOLOGY; PLANAR ARRAY; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT;

GENETIC SCREENING; GENETIC TESTING; HUMANS; LABORATORIES, HOSPITAL; LEUKEMIA; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSTIC TECHNIQUES; TECHNOLOGY, MEDICAL;

EID: 18844396774     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.5.3.409     Document Type: Review

References (89)

1. Hood L. A personal view of molecular technology and how it has changed biology. J. Proteome Res. 1, 399-409 (2002). Excellent review of the impact technology has had on revolutionizing our understanding of biology.
2. Rothman RE. Current Centers for Disease Control and Prevention guidelines for HIV counseling, testing, and referral: critical role of and a call to action for emergency physicians. Ann. Emerg. Med. 44, 31-42 (2004).
3. Sebastian J, Faruki H. Update on HIV resistance and resistance testing. Med. Res. Rev. 24, 115-125 (2004).
4. DeRisi J, Penland L, Brown PO et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genet. 14, 457-460 (1996).
5. Heller RA, Schena M, Chai A et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl Acad. Sci. USA 94, 2150-2155 (1997).
6. Khan J, Simon R, Bittner M et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58, 5009-5013 (1998).
7. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nature Genet. 21, 48-50 (1999).
8. Chan WC, Huang JZ. Gene expression analysis in aggressive NHL. Ann. Hematol. 80(Suppl. 3), B38-B41 (2001).
9. Hegde P, Qi R, Gaspard R et al. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res. 61, 7792-7797 (2001).
10. Oostlander A, Meijer G, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin. Genet. 66, 488-495 (2004).
11. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002).
12. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
13. Burczynski ME, Oestreicher JL, Cahilly MJ et al. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr. Mol. Med. 5, 83-102 (2005).
14. Man TK, Lu XY, Jaeweon K et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4, 45 (2004).
15. Uttamchandani M, Huang X, Chen GY, Tan LP, Yao SQ. Application of microarrays in high-throughput enzymatic profiling. Mol. Biotechnol. 28, 227-240 (2004).
16. Zhu H, Bilgin M, Bangham R et al. Global analysis of protein activities using proteome chips. Science 293, 2101-2105 (2001).
17. Al Kuraya K, Simon R, Sauter G. Tissue microarrays for high-throughput molecular pathology. Ann. Saudi Med. 24, 169-174 (2004).
18. Braunschweig T, Chung JY, Hewitt SM. Perspectives in tissue microarrays. Comb. Chem. High Throughput Screen. 7, 575-585 (2004).
19. DNA Amplification: Current Technologies and Applications. Demidov VV, Broude NE (Eds), Horizon Bioscience, Norfolk, UK, 335 (2004).
20. Andras SC, Power JB, Cocking EC, Davey MR. Strategies for signal amplification in nucleic acid detection. Mol. Biotechnol. 19, 29-44 (2001).
21. Lisby G. Application of nucleic acid amplification in clinical microbiology. Methods Mol. Biol. 92, 1-29 (1998).
22. Vanecchoutte M, Van Eldere J. The possibilities and limitations of nucleic acid amplification technology in diagnostic microbiology. J. Med. Microbiol. 46, 188-194 (1997).
23. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc. Natl Acad. Sci. USA 87, 1663-1667 (1990). Multistep procedures for RNA amplification that have enabled researchers to perform microarray analysis of precious clinical samples.
24. Compton J. Nucleic acid sequence-based amplification. Nature 350, 91-92 (1991).
25. Guatelli JC, Whitfield KM, Kwoh DY, Barringer KJ, Richman DD, Gingeras TR. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. PNAS 87, 1874-1878 (1990).
26. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nature Genet. 21, 20-24 (1999).
27. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SPA. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. PNAS 91, 5022-5026 (1994).
28. Jarvinen AK, Hautaniemi S, Edgren H et al. Are data from different gene expression microarray platforms comparable? Genomics 83, 1164-1168 (2004).
29. Mecham BH, Klus GT, Strovel J et al. Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nucleic Acids Res. 32, e74 (2004).
30. Wang Y, Ma WL, Mao XM et al. Design and preparation of oligonucleotide microarray for vaccinia virus detection. Di Yi Jun Yi Da Xue Xue Bao 24, 180-183 (2004).
31. Ramakrishnan R, Dorris D, Lublinsky A et al. An assessment of Motorola CodeLink™ microarray performance for gene expression profiling applications. Nucleic Acids Res. 30, e30 (2002).
32. Dumur CI, Nasim S, Best AM et al. Evaluation of quality-control criteria for microarray gene expression analysis. Clin. Chem. 50, 1994-2002 (2004). Identifies parameters affecting quality control of high-density microarrays for the clinical laboratory, emphasizing standard operating procedures and evaluating the quality of the RNA.
33. Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nature Genet. 29, 365-371 (2001). The large quantity of data generated by a microarray experiment and the ancillary information needed to interpret the results fostered the need for the Minimum Information About a Microarray Experiment guidelines. Making core information of the data publically available is required for many journal submissions and enables researchers to reproduce the analysis and conclusions of the original authors.
34. Shi L, Tong W, Goodsaid F et al. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev. Mol. Diagn. 4, 761-777 (2004).
35. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362, 1439-1444 (2003).
36. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365, 488-492 (2005). Critical review of previous microarray experiments emphasizes caution in implementing predictive gene lists determined by microarray analysis. In five of seven studies patients were not classified better than chance.
37. Edelmann L, Hashmi G, Song Y, Han Y, Kornreich R, Desnick R. Cystic fibrosis carrier screening: validation of a novel method using BeadChip technology. Genet. Med. 6, 431-438 (2004).
38. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques (Suppl. 56-58), 60-61 (2002).
39. Gunderson KL, Kruglyak S, Graige MS et al. Decoding randomly ordered DNA arrays. Genome Res. 14, 870-877 (2004).
40. The International HapMap Consortium. The International HapMap Project. Nature 426, 789-796 (2003).
41. Kuhn K, Baker SC, Chudin E et al. A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res. 14, 2347-2356 (2004). Detailed characterization of immobilized bead arrays for gene expression profiling.
42. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr. Advanced multiplexed analysis with the FlowMetrix™ system. Clin. Chem. 43, 1749-1756 (1997).
43. Armstrong B, Stewart M, Mazumder A. Suspension arrays for high-throughput, multiplexed single nucleotide polymorphism genotyping. Cytometry 40, 102-108 (2000).
44. Chen J, Iannonc MA, Li MS et al. A microsphcrc-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension. Genome Res. 10, 549-557 (2000).
45. Gilburd B, Abu-Shakra M, Shoenfeld Y et al. Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation - a homogeneous, multiplexed system. Clin. Dev. Immunol. 11, 53-56 (2004).
46. Hildesheim A, Ryan RL, Rinehart E et al. Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiol. Biomarken Prev. 11, 1477-1484 (2002).
47. Defoort JP, Martin M, Casano B, Prato S, Camilla C, Pert V. Simultaneous detection of multiplex-amplified human immunodeficiency virus typel RNA, hepatitis C virus RNA, and hepatitis B virus DNA using a flow cytometer microsphere-based hybridization assay. J. Clin. Microbiol. 38, 1066-1071 (2000).
48. Ye F, Li M-S, Tayolor JD et al. Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification. Hum. Mut. 17, 305-316 (2001).
49. Bortolin S, Black M, Modi H et al. Analytical validation of the Tag-It high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms. Clin. Ghent. 50, 2028-2036 (2004). An advantage of the Tag-It approach is that the genotype is effectively amplified and the bead array becomes a universal component of any DNA-based test, regardless of the application.
50. Johnson SC, Marshall DJ, Harms G et al. Multiplexed genetic analysis using an expanded genetic alphabet. Clin. Chem. 50, 2019-2027 (2004). Isonucleotides can effectively expand the range of hybridization and detection capabilities of DNA hybridization assays, as described in this paper for detection of cystic fibrosis mutations.
51. Hurley JD, Engle LJ, Davis JT, Welsh AM, Landers JE. A simple, bead-based approach for multi-SNP molecular haplotyping. Nucleic Acids Res. 32, e186 (2004).
52. Hadd AG, Laosinchai-Wolf W, Novak CR et al. Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms. J. Mol. Diagn. 6, 348-355 (2004).
53. Johnson SC, Sherrill CB, Marshall DJ, Moser MJ, Prudent JR. A third base pair for the polymerase chain reaction: inserting isoC and isoG. Nucleic Acids Res. 32, 1937-1941 (2004).
54. Yang L, Tran DK, Wang X. BADGE, Beads Array for the Detection of Gene Expression, a high-throughput diagnostic bioassay. Genome Res. 11, 1888-1898 (2001).
55. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3, 149-154 (2001).
56. Strom CM, Huang D, Buller A et al. Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples. Genet. Med. 4, 289-296 (2002).
57. Buller A, Olson S, Redman JB, Hantash F, Chen R, Strom CM. Frequency of the cystic fibrosis 3199del6 mutation in individuals heterozygous for I148T. Genet. Med. 6, 108-109 (2004).
58. Check W. CF Carrier screening - making it meaningful. CAP Today 17, 34-41 (2003).
59. Watson MS, Cutting GR, Desnick RJ et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet. Med. 6, 387-391 (2004).
60. Tsongalis GJ, Belloni DR, Grody WW. Cystic fibrosis mutation analysis: how many is enough? Genet. Med. 6, 456-458 (2004). Authors rebut the 'more is better' argument for cystic fibrosis mutation screening.
61. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet. Gynecol. 104, 425-428 (2004).
62. Rosenberg D, Cutler R. Tay-Sachs carrier detection by mechanized serum hexosaminidase assay. Clin. Chim. Acta 53, 247-253 (1974).
63. Ellis NA, Ciocci S, Proytcheva M, Lennon D, Groden J, German J. The Ashkenazic Jewish Bloom syndrome mutation blmAsh is present in non-Jewish Americans of Spanish ancestry. Am. J. Hum. Genet. 63, 1685-1693 (1998).
64. Feigenbaum A, Moore R, Clarke J et al. Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am. J. Med. Genet. A124, 142-147 (2004).
65. Dong J, Edelmann L, Bajwa AM, Kornreich R, Desnick RJ. Familial dysautonomia: detection of the IKBKAP IVS20(+6T→C) and R696P mutations and frequencies among Ashkenazi Jews. Am. J. Med. Genet. 110, 253-257 (2002).
66. Firon N, Eyal N, Kolodny EH, Horowitz M. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. Am. J. Hum. Genet. 46, 527-532 (1990).
67. Wang ZH, Zeng B, Pastores GM, Raksadawan N, Ong E, Kolodny EH. Rapid detection of the two common mutations in Ashkenazi Jewish patients with mucolipidosis Type IV. Genet. Test. 5, 87-92 (2001).
68. Harzer K, Rolfs A, Bauer P et al. Niemann-Pick disease type A and B are clinically but also enzymatically heterogeneous: pitfall in the laboratory diagnosis of sphingomyelinase deficiency associated with the mutation Q292 K. Neuropediatrics 34, 301-306 (2003).
69. Amir N, Zlotogora J, Bach G. Mucolipidosis Type IV: clinical spectrum and natural history. Pediatrics 79, 953-959 (1987).
70. Auerbach AD. Fanconi anemia: genetic testing in Ashkenazi Jews. Genet. Test. 1, 27-33 (1997).
71. Staudt LM. Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. 348, 1777-1785 (2003).
72. Bagg A. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. J. Mol. Diagn. 4, 1-10 (2002).
73. Wallace J, Zhou Y, Usmani GN et al. BARCODE-ALL: accelerated and cost-effective genetic risk stratification in acute leukemia using spectrally addressable liquid bead microarrays. Leukemia 17, 1404-1410 (2003).
74. Chen IM, Chakerian A, Combs D, Garner K, Viswanatha DS. Post-PCR multiplex fluorescent ligation detection assay and flow cytometry for rapid detection of gene-specific translocations in leukemia. Am. J. Clin. Pathol. 122, 783-793 (2004).
75. Ross ME, Mahfouz R, Onciu M et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104, 3679-3687 (2004).
76. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002).
77. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B-cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101, 11755-11760 (2004).
78. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101, 2999-3004 (2004).
79. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1, 882-891 (2003).
80. Pfeffer S, Zavolan M, Grasser FA et al. Identification of virus-encoded microRNAs. Science 304, 734-736 (2004).
81. Bagg A. Role of molecular studies in the classification of lymphoma. Expert Rev. Mol. Diagn. 4, 83-97 (2004).
82. Dillon D, Zheng K, Costa J. Rapid, efficient genotyping of clinical tumor samples by laser-capture microdissection/PCR/SSCP. Exp. Mol. Pathol. 70, 195-200 (2001).
83. Rook MS, Delach SM, Deyneko G, Worlock A, Wolfe JL. Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping. Am. J. Pathol. 164, 23-33 (2004).
84. Weston AD, Hood L. Systems biology, proteomics, and the future of healthcare: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3, 179-196 (2004).
85. Penn SG, He L, Natan MJ. Nanoparticles for bioanalysis. Curr. Opin. Chem. Biol. 7, 609-615 (2003). Advances in nanobiotechnology may soon impact our capabilities for multiplexed analysis; novel nanoparticles and coding strategies are reviewed.
86. Wu X, Liu H, Liu J et al. Immunofluorescent labeling of cancer marker HeR2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol. 21, 41-46 (2003).
87. Xu H, Sha MY, Wong EY et al. Multiplexed SNP genotyping using the Qbead system: a quantum dot-encoded microsphere-based assay. Nucleic Acids Res. 31, e43 (2003).
88. Finkel NH, Lou X, Wang C, He L. Barcoding the microworld. Anal. Chem. 76, 352A-359A (2004).
89. Nicewarner-Pena SR, Freeman RG, Reiss BD et al. Submicro meter metallic barcodes. Science 294, 137-141 (2001).